Shanghai Xuantai Haimen Pharmaceutical

Sinotherapeutics (Shanghai Xuantai Pharmaceutical) is a commercial-stage pharmaceutical company headquartered in Shanghai, China, specializing in the development and manufacturing of high-end drug formulations. Since its founding in 2012, the company has built a sophisticated technology platform focused on solubilization, sustained-release, and complex oral solids, allowing it to compete in global markets including the U.S. and China. Its commercial portfolio features a range of oncology, anti-infective, and cardiovascular products such as olaparib, posaconazole, and macitentan. The company's primary manufacturing facility, located in Haimen, Jiangsu, is a state-of-the-art site that has successfully passed inspections by the US FDA and China's NMPA. Sinotherapeutics also operates as a CDMO and CRO, providing formulation development and manufacturing services to international biotech and pharmaceutical partners.